Conflict of Interest: The authors are employees of NuPathe, Inc.
Sumatriptan Iontophoretic Transdermal System: History, Study Results, and Use in Clinical Practice
Version of Record online: 11 SEP 2013
© 2013 American Headache Society
Headache: The Journal of Head and Face Pain
Special Issue: New Delivery Systems
Volume 53, Issue Supplement S2, pages 34–42, September 2013
How to Cite
Pierce, M., O'Neill, C., Felker, E. and Sebree, T. (2013), Sumatriptan Iontophoretic Transdermal System: History, Study Results, and Use in Clinical Practice. Headache: The Journal of Head and Face Pain, 53: 34–42. doi: 10.1111/head.12182
- Issue online: 11 SEP 2013
- Version of Record online: 11 SEP 2013
- Manuscript Accepted: 16 MAY 2013
Nausea is a common symptom of migraine, and current treatment guidelines recommend non-oral formulations for nauseated or vomiting patients. Transdermal delivery of sumatriptan, a 5-hydroxytryptamine1B1D agonist with established efficacy in patients with migraine, represents a novel approach to acute treatment. The sumatriptan iontophoretic transdermal system circumvents the gastrointestinal tract by using low-level electrical energy to transport sumatriptan across the skin. In multiple well-controlled studies, the sumatriptan transdermal system has shown that it provides consistent drug delivery with low interpatient variability, rapid relief of migraine pain and associated symptoms, and an excellent overall safety profile, with a low incidence of triptan-sensation adverse events. Patients and health care professionals who have used the sumatriptan transdermal system give it high ratings for ease of use/application. The sumatriptan transdermal system will allow a wide range of patients, especially those who experience migraine-related nausea or vomiting, to receive the benefits of migraine-specific therapy.